Inclusion Criteria:

- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

- Stage IV or IIIB with malignant pleural effusion, also locally advanced NSCLC not
otherwise amenable to local treatment (surgery or radiotherapy)

- One line of prior chemotherapy

- Measurable disease

- Greater or equal to 18 years

- Life expectancy of at least 12 weeks

- ECOG performance status 0-2

- Laboratory requirements at entry:

- Blood cell counts:

- Absolute neutrophils ≥ 1.0 x 109/L

- Platelets ≥100 x 109/L

- Hemoglobin ≥ 10 g/dl

- Renal function:

- Creatinine clearance ≥ 45 mL/min

- Hepatic functions:

- ASAT and ALAT ≤ 3 x UNL

- Alkaline phosphatase ≤ 5 x UNL

- Signed informed consent prior to start protocol specific requirements

- Pregnancy test (β-HCG) must be negative (needed only for women of childbearing
potential).

Exclusion Criteria:

- Known brain metastases or meningeal carcinomatosis

- Other serious concomitant illness of medical conditions:

- Congestive heart failure or angina pectoris except if it is medically controlled.

- Previous history of myocardial infarction within 1 year from study entry.

- Uncontrolled hypertension or arrhythmias

- Implanted pacemaker, defibrillator or deep brain stimulation device

- History of significant neurologic or psychiatric disorders including dementia or
seizures

- Active infection requiring iv antibiotics

- Active ulcer, unstable diabetes mellitus or other contra-indication to corticosteroid
therapy

- Concurrent treatment with other experimental drugs

- Participation in clinical trials with other experimental agents within 30 days of
study entry

- Psychological, familial, sociological or geographical conditions which don't permit
medical follow-up and compliance with the study protocol